Thera-SAbDab

ANIVOVETMAB

>   Structural Summary
TherapeuticAnivovetmab
TargetVP2 (Canine)
Heavy ChainQVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA
Light ChainDIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure3iy6 [Fvs: BA], 3jcx [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Anivovetmab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 94.71%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
anivovetmab Q V Q L K E S G P G L V A P S Q T L S L T C T V S G F S L S S Y H V H W V R Q P P G K G L E W L G V M W N D G D T S Y N L A L N S R L S I S R D T S K S Q V F F K M S S L Q T E D T A T Y Y C A R P E L P G L T Y G V W F P Y W G Q G T L V T V S A
3iy6 - - - - - - S G P G L V Q P S Q T L S L T C T V S G F S L S S Y H V H W V R Q P P G K G L E W L G V M W N D G D T S Y N L A L N S R L S I S R D T S K S Q V F F K M S S L Q T E D T A T Y Y C A R P E L P G L T Y G V W F P Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
anivovetmab D I V M T Q T P A S M S I S V G D R V T M N C K A S Q N V D S N V D W Y Q Q K T G Q S P N L L I Y K A S N R N T G V P D R F T G S G S G T D F T F T I S N M Q A E D L A V Y Y C M Q S T S Y P L T F G S G T K L E I K
3iy6 - - L M T Q I P A S M S I S V G D R V T M N C K A S Q N V D S N V D W Y Q Q K T G Q S P N L L I Y K A S N R N T G V P D R F T G S G S G T D F T F T I S N M Q A E D L A V Y Y C M Q S T S Y P L T F G S G T K L E I K
Sequence identity: 94.71%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
anivovetmab Q V Q L K E S G P G L V A P S Q T L S L T C T V S G F S L S S Y H V H W V R Q P P G K G L E W L G V M W N D G D T S Y N L A L N S R L S I S R D T S K S Q V F F K M S S L Q T E D T A T Y Y C A R P E L P G L T Y G V W F P Y W G Q G T L V T V S A
3jcx - - - - - - S G P G L V Q P S Q T L S L T C T V S G F S L S S Y H V H W V R Q P P G K G L E W L G V M W N D G D T S Y N L A L N S R L S I S R D T S K S Q V F F K M S S L Q T E D T A T Y Y C A R P E L P G L T Y G V W F P Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
anivovetmab D I V M T Q T P A S M S I S V G D R V T M N C K A S Q N V D S N V D W Y Q Q K T G Q S P N L L I Y K A S N R N T G V P D R F T G S G S G T D F T F T I S N M Q A E D L A V Y Y C M Q S T S Y P L T F G S G T K L E I K
3jcx - - L M T Q I P A S M S I S V G D R V T M N C K A S Q N V D S N V D W Y Q Q K T G Q S P N L L I Y K A S N R N T G V P D R F T G S G S G T D F T F T I S N M Q A E D L A V Y Y C M Q S T S Y P L T F G S G T K L E I K
>   Metadata
FormatCanine Whole mAb
IsotypeG2
Highest Clinical Trial (Aug '22)Unknown
Estimated Status (Aug '22)Active
Recorded Developmental TechnologyTBC
INN Year Proposed2022
INN Year RecommendedNone
Companies InvolvedTBC
Conditions ApprovedTBC
Conditions ActiveTBC
Conditions DiscontinuedTBC
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy